Browse studies

Find your next paid study

135 recruiting studies matching your filters

MyeloGen: Germline Testing for Predisposition to Myeloid Malignancies

The goal of this research study is to evaluate the feasibility of germline genetic testing using the investigational MyeloGen Gene Panel in adult participants …

Myeloid MalignancyGenetic Predisposition to DiseaseMyeloid Hematological Malignancies

Estimated

~$10 – $1,125

Actual pay is set by the research site.

Christopher ReillyNCT07112287

Observational

The Florida Partnership for Adding Social Context to Address Cancer Survivorship Outcomes (Florida ASCENT)

The goal of this clinical trial is to adapt, implement, and evaluate MyCarePulse and ASCENT patient navigator to overcome barriers to care among patients with …

CancerFood DeprivationFood Habits+11 more

Estimated

~$10 – $750

Actual pay is set by the research site.

University of FloridaNCT07042243

Phase 3

A Long-term Follow-up Study of Subjects With β-thalassemia or Sickle Cell Disease Treated With Autologous CRISPR-Cas9 Modified Hematopoietic Stem Cells (CTX001)

This is a multi-site, open- label rollover study to evaluate the long-term safety and efficacy of CTX001 in pediatric and adult participants who received CTX00…

Beta-ThalassemiaThalassemiaSickle Cell Disease+4 more

Estimated

~$50 – $2,100

Actual pay is set by the research site.

Vertex Pharmaceuticals IncorporatedNCT04208529

Phase 1

A Pilot Study of Haploidentical Hematopoietic Stem Cell Transplantation With Ex Vivo TCR Alpha/Beta and CD19 Depletion in Pediatric Hematologic Malignancies

This single arm pilot phase I study with safety run-in is designed to estimate the safety and efficacy of a familial mismatched or haploidentical hematopoietic…

Pediatric Hematologic Malignancies

Estimated

~$150 – $3,000

Actual pay is set by the research site.

Washington University School of MedicineNCT05011422

Observational

Advancing Health Information Exchange (HIE) During Inter-hospital Transfer (IHT) to Improve Patient Outcomes

Sub-optimal transfer of clinical information during inter-hospital transfer (IHT, the transfer of patients between acute care hospitals) is common and can lead…

InfectionsHeart FailureCOPD Exacerbation+13 more

Estimated

~$10 – $750

Actual pay is set by the research site.

Brigham and Women's HospitalNCT05443321

Long-term Follow-up After Adoptive Transfer of Genetically Modified Cell Products

Human gene therapy products are designed to achieve therapeutic effect through genetic modifications of human cells using retroviral or lentiviral vectors, res…

Relapsed Hematologic MalignancyRefractory Hematologic Malignancy

Estimated

~$10 – $750

Actual pay is set by the research site.

St. Jude Children's Research HospitalNCT05713214

Phase 2

Randomized Pilot Study of Ruxolitinib for Switch-Maintenance Prophylaxis of Graft-versus-Host Disease in Allogeneic Hematopoietic Cell Transplantation After Intermediate-Dose Post-Transplant Cyclophosphamide (Rux Switch-Maintenance in Intermediate PTCY: RuSMa-PTCY) in Comparison to Full-Dose PTCY

The researchers are doing this study to compare 2 different GVHD prevention (prophylaxis) approaches. The researchers will see which approach is good or more e…

Hematologic Malignancies

Estimated

~$75 – $2,000

Actual pay is set by the research site.

Memorial Sloan Kettering Cancer CenterNCT07359859

Phase 1

Phase I/II Study Using Prophylactic Donor Lymphocyte Infusion Early Post-Transplant After Allogeneic Hematopoietic Cell Transplantation Using Post-Transplantation Cyclophosphamide for High-Risk Hematologic Malignancies

Background: People with blood cancers often receive blood or bone marrow transplants. But even with these treatments, the risk of relapse is high. Researchers…

Hematologic Neoplasms

Estimated

~$500 – $6,750

Actual pay is set by the research site.

National Cancer Institute (NCI)NCT05327023

Long-term Follow-up Study for Participants of Kite-Sponsored Interventional Studies Treated With Gene-Modified Cells

The goal of this clinical study is to learn more about the long-term safety, effectiveness and prolonged action of Kite study drugs, axicabtagene ciloleucel, b…

Solid and Hematological MalignanciesAutoimmune Diseases

Estimated

Pay not disclosed — ask the coordinator

Kite, A Gilead CompanyNCT05041309

Phase 1

Tolerability Study of Trichostatin A In Subjects With Relapsed or Refractory Hematologic Malignancies

The aim of this study is to investigate the safety and tolerability of trichostatin A in individuals with relapsed or refractory hematologic malignancies.

Relapsed or Refractory Hematologic Malignancies

Estimated

~$150 – $4,200

Actual pay is set by the research site.

Vanda PharmaceuticalsNCT03838926

ATHN Transcends: A Natural History Cohort Study of the Safety, Effectiveness, and Practice of Treatment in People With Non-Neoplastic Hematologic Disorders

In parallel with the growth of ATHN's clinical studies, the number of new therapies for all blood disorders is increasing significantly. Some of the recently F…

Hematologic DisorderBleeding DisorderConnective Tissue Disorder+10 more

Estimated

~$10 – $1,125

Actual pay is set by the research site.

American Thrombosis and Hemostasis NetworkNCT04398628

Phase 3

A Long-term Follow-up Study for Patients Treated With Galapagos CAR T-cell Therapies

This is a long-term follow-up study for participants treated with Galapagos (GLPG) CAR T-cell therapies to evaluate the long-term safety and efficacy of GLPG C…

Hematological Malignancies

Estimated

~$50 – $2,100

Actual pay is set by the research site.

Lakefront Biotherapeutics NVNCT06652633